Abstract

Assessment of patient satisfaction with ebastine fast-dissolving tablets in patients suffering from allergic rhinitis

Author(s): Albert Roger, Josep Fortea, M Jose Plazas, Sheila Mora and Maite Artes

Objective: The aim of this study was to assess patient satisfaction with ebastine fast-dissolving tablets (FDT) using the Treatment Satisfaction Questionnaire for Medication (TSQM). Research, design and methods: This was an international, multicenter, observational study involving patients with at least 1‑year history of intermittent allergic rhinitis or persistent allergic rhinitis and who had received a prescription for ebastine FDT (20 mg) in the last 2 months. Investigators collected demographic data, medical history, a completed TSQM questionnaire, and responses regarding perception of onset of action, intensity of rhinitis symptoms, tolerability and their preference compared with previous therapy. Results: Validated TSQM questionnaires were collected from 461 patients and the overall ratings for effectiveness, side effects, convenience and global satisfaction were all very high for ebastine FDT. A total of 79% of patients reported a fast or very fast onset of action. On the last day of treatment patients reported a statistically significant (p < 0.001) improvement in the intensity and relief of symptoms of allergic rhinitis. A total of 95% of patients reported good or very good tolerability with ebastine FDT. Compared with the patient’s experience with previous therapy, ebastine FDT was considered better or much better for: efficacy (81%), tolerability (73%), onset of action (79%) and convenience (94%). A total of 94% of patients indicated that they would like to use ebastine FDT again. Conclusion: Ebastine FDT was associated with a very high satisfaction rate and significant relief of rhinitis symptoms and, consequently, patients reported a preference for the FDT formulation over previous antihistamines that they had used.